BLEPHAMIDE

Manufacturer
Physicians Total Care, Inc.
Effective date
2013-11-15
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
1
Source
full-release
Hydrated at
2026-05-31 20:17:25

Label at a glance#

ProductBLEPHAMIDE
Active ingredientsulfacetamide sodium, prednisolone acetate
Label structure10 sections

Indications and uses

A steroid/anti-infective combination is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. Ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of co...

Dosage and administration

SHAKE WELL BEFORE USING. Two drops should be instilled into the conjunctival sac every four hours during the day and at bedtime. Not more than 20 milliliters should be prescribed initially, and the prescription should not be refilled without further evaluation as outlined in PRECAUTIONS above. BLEPHAMIDE ® dosage may be reduced, but care should be taken not to discontinue therapy prematurely. In chronic conditions...

Label contents#

Full prescribing information#

DESCRIPTION

DESCRIPTION SECTION

BLEPHAMIDE® ophthalmic suspension is a topical anti-inflammatory/anti-infective combination product for ophthalmic use.

Structural Formulas:

Structural Formulas
Structural Formulas

Chemical Names:

SPL UNCLASSIFIED SECTION

Sulfacetamide sodium: N-sulfanilylacetamide monosodium salt monohydrate.

Prednisolone acetate: 11ß, 17, 21-trihydroxypregna-1, 4-diene-3, 20-dione 21-acetate.

Contains:

Actives: sulfacetamide sodium 10%, prednisolone acetate (microfine suspension) 0.2%.

Preservative: benzalkonium chloride (0.004%). Inactives: edetate disodium; polysorbate 80; polyvinyl alcohol 1.4%; potassium phosphate, monobasic; purified water; sodium phosphate, dibasic; sodium thiosulfate; hydrochloric acid and/or sodium hydroxide to adjust the pH (6.6 to 7.2).

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Corticosteroids suppress the inflammatory response to a variety of agents and they probably delay or slow healing. Since corticosteroids may inhibit the body's defense mechanism against infection, a concomitant antibacterial drug may be used when this inhibition is considered to be clinically significant in a particular case.

When a decision to administer both a corticosteroid and an antibacterial is made, the administration of such drugs in combination has the advantage of greater patient compliance and convenience, with the added assurance that the appropriate dosage of both drugs is administered. When both types of drugs are in the same formulation, compatibility of ingredients is assured and the correct volume of drug is delivered and retained. The relative potency of corticosteroids depends on the molecular structure, concentration and release from the vehicle.

MICROBIOLOGY SECTION

Microbiology: Sulfacetamide sodium exerts a bacteriostatic effect against susceptible bacteria by restricting the synthesis of folic acid required for growth through competition with p-aminobenzoic acid.

Some strains of these bacteria may be resistant to sulfacetamide or resistant strains may emerge in vivo.

The anti-infective component in these products is included to provide action against specific organisms susceptible to it. Sulfacetamide sodium is active in vitro against susceptible strains of the following microorganisms: Escherichia coli, Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus (viridans group), Haemophilus influenzae, Klebsiella species, and Enterobacter species. This product does not provide adequate coverage against: Neisseria species, Pseudomonas species, and Serratia marcescens (see INDICATIONS AND USAGE).

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

A steroid/anti-infective combination is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists.

Ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of corticosteroid use in certain infective conjunctivitides is accepted to obtain diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns or penetration of foreign bodies.

The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye.

The particular antibacterial drug in this product is active against the following common bacterial eye pathogens: Escherichia coli, Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus (viridans group), Haemophilus influenzae, Klebsiella species, and Enterobacter species. This product does not provide adequate coverage against: Neisseria species, Pseudomonas species, and Serratia marcescens.

A significant percentage of staphylococcal isolates are completely resistant to sulfa drugs.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

BLEPHAMIDE® ophthalmic suspension is contraindicated in most viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures.

This product is also contraindicated in individuals with known or suspected hypersensitivity to any of the ingredients of this preparation, to other sulfonamides and to other corticosteroids. See WARNINGS. (Hypersensitivity to the antimicrobial component occurs at a higher rate than for other components.)

WARNINGS

WARNINGS SECTION

NOT FOR INJECTION INTO THE EYE.

Prolonged use of corticosteroids may result in ocular hypertension/glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision, and in posterior subcapsular cataract formation.

Acute anterior uveitis may occur in susceptible individuals, primarily Blacks.

Prolonged use of BLEPHAMIDE® ophthalmic suspension may suppress the host response and thus increase the hazard of secondary ocular infections. In those diseases causing thinning of the cornea or sclera, perforation has been known to occur with the use of topical corticosteroids. In acute purulent conditions of the eye, corticosteroids may mask infection or enhance existing infection.

If the product is used for 10 days or longer, intraocular pressure should be routinely monitored even though it may be difficult in children and uncooperative patients. Corticosteroids should be used with caution in the presence of glaucoma. Intraocular pressure should be checked frequently.

A significant percentage of staphylococcal isolates are completely resistant to sulfonamides.

The use of steroids after cataract surgery may delay healing and increase the incidence of filtering blebs.

The use of ocular corticosteroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex). Employment of corticosteroid medication in the treatment of herpes simplex requires great caution.

Topical steroids are not effective in mustard gas keratitis and Sjögren's keratoconjunctivitis.

Fatalities have occurred, although rarely, due to severe reactions to sulfonamides including Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anemia and other blood dyscrasias. Sensitization may recur when a sulfonamide is readministered, irrespective of the route of administration.

If signs of hypersensitivity or other serious reactions occur, discontinue use of this preparation. Cross-sensitivity among corticosteroids has been demonstrated (see ADVERSE REACTIONS).

PRECAUTIONS

PRECAUTIONS SECTION

General:

GENERAL PRECAUTIONS SECTION

The initial prescription and renewal of the medication order beyond 20 milliliters of the suspension should be made by a physician only after examination of the patient with the aid of magnification, such as slit lamp biomicroscopy and, where appropriate, fluorescein staining. If signs and symptoms fail to improve after two days, the patient should be re-evaluated.

The possibility of fungal infections of the cornea should be considered after prolonged corticosteroid dosing. Use with caution in patients with severe dry eye. Fungal cultures should be taken when appropriate.

The p-aminobenzoic acid present in purulent exudates competes with sulfonamides and can reduce their effectiveness.

Information for Patients:

INFORMATION FOR PATIENTS SECTION

If inflammation or pain persists longer than 48 hours or becomes aggravated, the patient should be advised to discontinue use of the medication and consult a physician (see WARNINGS).

Contact lenses should not be worn during the use of this product.

This product is sterile when packaged. To prevent contamination, care should be taken to avoid touching the applicator tip to eyelids or to any other surface. The use of this bottle by more than one person may spread infection. Keep bottle tightly closed when not in use. Protect from light. Sulfonamide solutions darken on prolonged standing and exposure to heat and light. Do not use if solution has darkened. Yellowing does not affect activity. Keep out of the reach of children.

Laboratory Tests:

LABORATORY TESTS SECTION

Eyelid cultures and tests to determine the susceptibility of organisms to sulfacetamide may be indicated if signs and symptoms persist or recur in spite of the recommended course of treatment with BLEPHAMIDE® ophthalmic suspension.

Drug Interactions:

DRUG INTERACTIONS SECTION

BLEPHAMIDE® ophthalmic suspension is incompatible with silver preparations. Local anesthetics related to p-aminobenzoic acid may antagonize the action of the sulfonamides.

Carcinogenesis, Mutagenesis, Impairment of Fertility:

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

Prednisolone has been reported to be noncarcinogenic. Long-term animal studies for carcinogenic potential have not been performed with sulfacetamide.

One author detected chromosomal nondisjunction in the yeast Saccharomyces cerevisiae following application of sulfacetamide sodium. The significance of this finding to topical ophthalmic use of sulfacetamide sodium in the human is unknown.

Mutagenic studies with prednisolone have been negative. Studies on reproduction and fertility have not been performed with sulfacetamide. A long-term chronic toxicity study in dogs showed that high oral doses of prednisolone prevented estrus. A decrease in fertility was seen in male and female rats that were mated following oral dosing with another glucocorticosteroid.

Pregnancy:

PREGNANCY SECTION

Teratogenic Effects: Pregnancy Category C. Animal reproduction studies have not been conducted with sulfacetamide sodium. Prednisolone has been shown to be teratogenic in rabbits, hamsters, and mice. In mice, prednisolone has been shown to be teratogenic when given in doses 1 to 10 times the human ocular dose. Dexamethasone, hydrocortisone and prednisolone were ocularly applied to both eyes of pregnant mice five times per day on days 10 through 13 of gestation. A significant increase in the incidence of cleft palate was observed in the fetuses of the treated mice. There are no adequate well-controlled studies in pregnant women dosed with corticosteroids.

Kernicterus may be precipitated in infants by sulfonamides being given systemically during the third trimester of pregnancy. It is not known whether sulfacetamide sodium can cause fetal harm when administered to a pregnant woman or whether it can affect reproductive capacity.

BLEPHAMIDE® ophthalmic suspension should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Nursing Mothers:

NURSING MOTHERS SECTION

It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk. Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. Systemically administered sulfonamides are capable of producing kernicterus in infants of lactating women. Because of the potential for serious adverse reactions in nursing infants from sulfacetamide sodium and prednisolone acetate ophthalmic suspensions, a decision should be made whether to discontinue nursing or to discontinue the medication.

Pediatric Use:

PEDIATRIC USE SECTION

Safety and effectiveness in pediatric patients below the age of six have not been established.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

Adverse reactions have occurred with corticosteroid/antibacterial combination drugs which can be attributed to the corticosteroid component, the antibacterial component, or the combination. Exact incidence figures are not available since no denominator of treated patients is available.

Reactions occurring most often from the presence of the antibacterial ingredient are allergic sensitizations. Fatalities have occurred, although rarely, due to severe reactions to sulfonamides including Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anemia, and other blood dyscrasias (See WARNINGS).

Sulfacetamide sodium may cause local irritation.

The reactions due to the corticosteroid component in decreasing order of frequency are: elevation of intraocular pressure (IOP) with possible development of glaucoma and infrequent optic nerve damage, posterior subcapsular cataract formation, and delayed wound healing.

Although systemic effects are extremely uncommon, there have been rare occurrences of systemic hypercorticoidism after use of topical corticosteroids.

Corticosteroid-containing preparations can also cause acute anterior uveitis or perforation of the globe. Mydriasis, loss of accommodation and ptosis have occasionally been reported following local use of corticosteroids.

SPL UNCLASSIFIED SECTION

Secondary infection: The development of secondary infection has occurred after use of combinations containing corticosteroids and antibacterials. Fungal and viral infections of the cornea are particularly prone to develop coincidentally with long-term applications of corticosteroid. The possibility of fungal invasion must be considered in any persistent corneal ulceration where corticosteroid treatment has been used.

Secondary bacterial ocular infection following suppression of host responses also occurs.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

SHAKE WELL BEFORE USING. Two drops should be instilled into the conjunctival sac every four hours during the day and at bedtime.

Not more than 20 milliliters should be prescribed initially, and the prescription should not be refilled without further evaluation as outlined in PRECAUTIONS above.

BLEPHAMIDE® dosage may be reduced, but care should be taken not to discontinue therapy prematurely. In chronic conditions, withdrawal of treatment should be carried out by gradually decreasing the frequency of application.

If signs and symptoms fail to improve after two days, the patient should be re-evaluated (see PRECAUTIONS).

HOW SUPPLIED

HOW SUPPLIED SECTION

BLEPHAMIDE® (sulfacetamide sodium–prednisolone acetate ophthalmic suspension, USP) is supplied sterile in opaque white LDPE plastic bottles and white dropper tips with white high impact polystyrene (HIPS) caps as follows:

5 mL in 10 mL bottle — NDC 54868-0634-1
  10 mL in 15 mL bottle

Note: Protect from freezing. Shake well before using.

STORAGE AND HANDLING SECTION

Storage: Store at 8°-24°C (46°-75°F) in an upright position.

PROTECT FROM LIGHT.

Sulfonamide solutions darken on prolonged standing and exposure to heat and light. Do not use if solution has darkened. Yellowing does not affect activity.

KEEP OUT OF REACH OF CHILDREN.

Rx only

Revised June 2004

© 2004 Allergan, Inc.
Irvine, CA 92612, U.S.A.
® marks owned by Allergan, Inc.
6580X
71735US10P

SPL UNCLASSIFIED SECTION

Distributed by:
Physicians Total Care, Inc.
Tulsa, OK        74146

Carton PDP

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

ALLERGAN

Rx Only

BLEPHAMIDE®

(sulfacetamide

sodium -

prednisolone

acetate

ophthalmic

suspension, USP)

10%/0.2%

sterile

10 mL

Carton PDP
Carton PDP

package label
package label

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
1012017BLEPHAMIDE 10 % / 0.2 % Ophthalmic SuspensionPSN1
1012015sulfacetamide sodium 10 % / prednisoLONE acetate 0.2 % Ophthalmic SuspensionPSN1
1012017prednisolone acetate 2 MG/ML / sulfacetamide sodium 100 MG/ML Ophthalmic Suspension [Blephamide]SBD1
1012015prednisolone acetate 2 MG/ML / sulfacetamide sodium 100 MG/ML Ophthalmic SuspensionSCD1
1012017Blephamide (prednisolone acetate 0.2 % / sulfacetamide sodium 10 % ) Ophthalmic SuspensionSY1
1012015prednisolone acetate 0.2 % / sulfacetamide sodium 10 % Ophthalmic SuspensionSY1

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
PREDNISOLONE Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813
SULFACETAMIDE Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

Product Linked Resources#

Resource, Code type, Value table
ResourceCode typeValueEquivalent identifiersSource image
BarcodeEAN-130311980022105GTIN-13: 0311980022105
EAN-13: 0311980022105
GTIN-12: 311980022105
UPC-A: 311980022105
GTIN storage (14 digits): 00311980022105
carton.jpg
Data codeCode 128012137carton.jpg
Data codeCode 128063400500000634.jpg

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
b3fecff3-fb51-4f66-b443-a130905bb500Product name120250804
3a7a0034-a88d-88c3-f43e-ea34c6a216deProduct name220250311
4b7700e3-6e0e-45e5-9d22-6f754d61386eProduct name220250304
9dbc4744-f7be-4393-b71a-e1bfd8b97659Product name220250218
9e44d9f9-cb87-3b0f-4c71-c8438d0dc2e5Product name220240102
4073022c-5d5d-48f5-82ed-091ad146a4b2Product name120171211
a0e37fa3-7f16-4fbf-bdb7-ae82cb1a553aProduct name120170309
af7d3306-1338-423f-839e-419aad9e8a86Product name120170309
9ffbd0ae-0bce-c086-b707-f0da5f8cd7c5Product name120150828
0304b7d2-7a07-d53b-750f-36012ae6612eProduct name120140508
18d57d04-4a34-a130-5dd5-b7fc47f3b567Product name120140508
379bc253-901a-e6e1-92b7-0fc574249e07Product name120140508
48b05f5d-d2fc-45ab-76e8-3cb5bd44890dProduct name120140508
64c0cc7e-6478-3ca1-8cd7-9a1251d5a3f6Product name120140508
73adedd8-aba8-27d9-78d9-2e3c4a3cf954Product name120140508
9ae74339-0a3d-82e9-5dd1-88bd2607bd6bProduct name120140508
9f10552a-9a7b-8e6c-3223-dc44310af6cfProduct name120140508
e44e38a9-2d9e-b0e2-cce9-490554639f3dProduct name120140508

FDA-Initiated Inactive NDC Indexing#

NDC, Effective, Action table
NDCEffectiveActionDocumentIndexing SPLRelated label
54868-0634-12019-09-24C16284748780-19350213a-44c9-c013-e053-90daa90a1393BLEPHAMIDE ® (sulfacetamide sodium – prednisolone acetate ophthalmic suspension, USP) 10%/0.2%

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
54868-0634-1BLEPHAMIDE5 mL in 1 BOTTLE, DROPPERSUSPENSION/ DROPS51
54868-0634-1BLEPHAMIDE1 in 1 CARTONSUSPENSION/ DROPS11

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
54868-0634BLEPHAMIDE (SULFACETAMIDE SODIUM AND PREDNISOLONE ACETATE) SUSPENSION/ DROPS [PHYSICIANS TOTAL CARE, INC.]12 package rows20131115_69465827-dd70-483e-84c7-ced49af5d189.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
54868-0634-1ML - Milliliter54868-0634232c50ce-fbd4-4b49-8a63-e16bfc13b75e12013-12-02
11980-022-05ML - Milliliter11980-022814682b1-cf85-4dcc-a43a-6026985f21f312012-07-24
11980-022-10ML - Milliliter11980-022255aa96c-c2b7-48eb-a4f5-6486a57191e112012-07-24

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
prednisolone acetateACTIVE INGREDIENT8B2807733D1
sulfacetamide sodiumACTIVE INGREDIENT4NRT660KJQ1
prednisoloneACTIVE MOIETY9PHQ9Y1OLM1
sulfacetamideACTIVE MOIETY4965G3J0F51
benzalkonium chlorideINACTIVE INGREDIENTF5UM2KM3W71
edetate disodiumINACTIVE INGREDIENT7FLD91C86K1
hydrochloric acidINACTIVE INGREDIENTQTT17582CB1
polysorbate 80INACTIVE INGREDIENT6OZP39ZG8H1
polyvinyl alcoholINACTIVE INGREDIENT532B59J9901
potassium phosphate, monobasicINACTIVE INGREDIENT4J9FJ0HL511
sodium hydroxideINACTIVE INGREDIENT55X04QC32I1
sodium phosphate, dibasicINACTIVE INGREDIENTGR686LBA741
sodium thiosulfateINACTIVE INGREDIENTHX1032V43M1
waterINACTIVE INGREDIENT059QF0KO0R1

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 16 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
54868-063454868-0634-1
11980-022

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 12 matching rows.

Source Document#

Source XML

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 10 · 561 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredientIID ingredientUNIIDosage form / routePotencyMaximum daily exposureMatch
polyvinyl alcoholPOLYVINYL ALCOHOL532B59J990SUSPENSION/ DROPS / OPHTHALMIC1.4 %w/vExact identifier — unii candidate
17 equally ranked IID candidates
sodium hydroxideSODIUM HYDROXIDE55X04QC32ILIQUID / INTRAVENOUSADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
polysorbate 80POLYSORBATE 806OZP39ZG8HINJECTION, POWDER, FOR SUSPENSION / INTRAMUSCULAR4 mgExact identifier — unii candidate
78 equally ranked IID candidates
sodium hydroxideSODIUM HYDROXIDE55X04QC32ISOLUTION / TOPICAL39 mgExact identifier — unii candidate
174 equally ranked IID candidates
sodium hydroxideSODIUM HYDROXIDE55X04QC32ISOLUTION / IONTOPHORESISADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
polyvinyl alcoholPOLYVINYL ALCOHOL532B59J990AEROSOL, FOAM / VAGINAL0.5 %w/wExact identifier — unii candidate
17 equally ranked IID candidates
sodium hydroxideSODIUM HYDROXIDE55X04QC32ISWAB / TOPICAL0.01 %w/wExact identifier — unii candidate
174 equally ranked IID candidates
sodium hydroxideSODIUM HYDROXIDE55X04QC32IINJECTION / DENTALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
sodium hydroxideSODIUM HYDROXIDE55X04QC32IINJECTION / INTRAVASCULARADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
potassium phosphate, monobasicMONOBASIC POTASSIUM PHOSPHATE4J9FJ0HL51INJECTION / INTRA-ARTICULAR0.3 %w/vExact identifier — unii candidate
19 equally ranked IID candidates
edetate disodiumEDETATE DISODIUM7FLD91C86KENEMA / RECTAL60 mgExact identifier — unii candidate
77 equally ranked IID candidates
edetate disodiumEDETATE DISODIUM7FLD91C86KSOLUTION / TOPICAL1 mgExact identifier — unii candidate
77 equally ranked IID candidates
edetate disodiumEDETATE DISODIUM7FLD91C86KSOLUTION / OPHTHALMIC4 mgExact identifier — unii candidate
77 equally ranked IID candidates
hydrochloric acidHYDROCHLORIC ACIDQTT17582CBLIQUID / ORAL4.46 mg/1mlExact identifier — unii candidate
148 equally ranked IID candidates
polyvinyl alcoholPOLYVINYL ALCOHOL532B59J990TABLET / ORAL165 mgExact identifier — unii candidate
17 equally ranked IID candidates
polysorbate 80POLYSORBATE 806OZP39ZG8HAEROSOL, FOAM / TOPICAL0.98 %w/wExact identifier — unii candidate
78 equally ranked IID candidates
edetate disodiumEDETATE DISODIUM7FLD91C86KINJECTION, SOLUTION / SUBCUTANEOUS2 mgExact identifier — unii candidate
77 equally ranked IID candidates
hydrochloric acidHYDROCHLORIC ACIDQTT17582CBINJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / SUBCUTANEOUSADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
hydrochloric acidHYDROCHLORIC ACIDQTT17582CBLOTION / TOPICALADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
sodium hydroxideSODIUM HYDROXIDE55X04QC32IINJECTION / INTRACAVITARYADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
hydrochloric acidHYDROCHLORIC ACIDQTT17582CBSUSPENSION / ORAL100 mgExact identifier — unii candidate
148 equally ranked IID candidates
hydrochloric acidHYDROCHLORIC ACIDQTT17582CBINJECTION / URETHRALADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
edetate disodiumEDETATE DISODIUM7FLD91C86KCAPSULE / ORAL5 mgExact identifier — unii candidate
77 equally ranked IID candidates
potassium phosphate, monobasicMONOBASIC POTASSIUM PHOSPHATE4J9FJ0HL51INJECTION / INTRAVENOUS68 mgExact identifier — unii candidate
19 equally ranked IID candidates
edetate disodiumEDETATE DISODIUM7FLD91C86KSOLUTION / RECTAL97 mgExact identifier — unii candidate
77 equally ranked IID candidates
edetate disodiumEDETATE DISODIUM7FLD91C86KGEL / VAGINAL5 mgExact identifier — unii candidate
77 equally ranked IID candidates
sodium hydroxideSODIUM HYDROXIDE55X04QC32IINJECTION, SOLUTION / SUBARACHNOIDADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
edetate disodiumEDETATE DISODIUM7FLD91C86KDROPS / NASAL0.1 mg/1mlExact identifier — unii candidate
77 equally ranked IID candidates
hydrochloric acidHYDROCHLORIC ACIDQTT17582CBINJECTION, SOLUTION / SUBMUCOSALADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
hydrochloric acidHYDROCHLORIC ACIDQTT17582CBSOLUTION / ORAL223 mgExact identifier — unii candidate
148 equally ranked IID candidates
hydrochloric acidHYDROCHLORIC ACIDQTT17582CBAEROSOL, FOAM / TOPICALADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
sodium hydroxideSODIUM HYDROXIDE55X04QC32IINJECTION / INTRAPLEURALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
edetate disodiumEDETATE DISODIUM7FLD91C86KINJECTION, POWDER, FOR SOLUTION / INTRAVENOUS6 mgExact identifier — unii candidate
77 equally ranked IID candidates
sodium hydroxideSODIUM HYDROXIDE55X04QC32IELIXIR / ORALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
sodium hydroxideSODIUM HYDROXIDE55X04QC32IINJECTION / SUBCUTANEOUS31.45 mgExact identifier — unii candidate
174 equally ranked IID candidates
edetate disodiumEDETATE DISODIUM7FLD91C86KINJECTION / INTRALESIONAL0.05 %w/vExact identifier — unii candidate
77 equally ranked IID candidates
polysorbate 80POLYSORBATE 806OZP39ZG8HINJECTION, SUSPENSION / SOFT TISSUE4 mgExact identifier — unii candidate
78 equally ranked IID candidates
sodium hydroxideSODIUM HYDROXIDE55X04QC32IINJECTION / EPIDURALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
polysorbate 80POLYSORBATE 806OZP39ZG8HSOLUTION / OPHTHALMIC8 mgExact identifier — unii candidate
78 equally ranked IID candidates
polysorbate 80POLYSORBATE 806OZP39ZG8HSPRAY, METERED / NASAL0.1 mg/1mlExact identifier — unii candidate
78 equally ranked IID candidates
sodium hydroxideSODIUM HYDROXIDE55X04QC32ISUSPENSION, EXTENDED RELEASE / INTRA-ARTICULARADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
edetate disodiumEDETATE DISODIUM7FLD91C86KSOLUTION / ORAL432 mgExact identifier — unii candidate
77 equally ranked IID candidates
benzalkonium chlorideBENZALKONIUM CHLORIDEF5UM2KM3W7SOLUTION / OPHTHALMIC2 %w/vExact identifier — unii candidate
24 equally ranked IID candidates
edetate disodiumEDETATE DISODIUM7FLD91C86KCONCENTRATE / ORAL20 mgExact identifier — unii candidate
77 equally ranked IID candidates
hydrochloric acidHYDROCHLORIC ACIDQTT17582CBCREAM / TOPICAL38 mgExact identifier — unii candidate
148 equally ranked IID candidates
sodium hydroxideSODIUM HYDROXIDE55X04QC32IINJECTION, SUSPENSION / INTRAMUSCULARADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
hydrochloric acidHYDROCHLORIC ACIDQTT17582CBSOLUTION/ DROPS / TOPICALADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
sodium phosphate, dibasicSODIUM PHOSPHATE, DIBASICGR686LBA74INJECTION / SUBCUTANEOUS14 mgExact identifier — unii candidate
14 equally ranked IID candidates
sodium hydroxideSODIUM HYDROXIDE55X04QC32ISOLUTION/ DROPS / OPHTHALMICADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
sodium hydroxideSODIUM HYDROXIDE55X04QC32ITABLET, EXTENDED RELEASE / ORAL13 mgExact identifier — unii candidate
174 equally ranked IID candidates
polyvinyl alcoholPOLYVINYL ALCOHOL532B59J990TABLET, FILM COATED / ORAL20 mgExact identifier — unii candidate
17 equally ranked IID candidates
polysorbate 80POLYSORBATE 806OZP39ZG8HINJECTION, POWDER, FOR SUSPENSION / INTRA-ARTICULAR5 mgExact identifier — unii candidate
78 equally ranked IID candidates
polysorbate 80POLYSORBATE 806OZP39ZG8HINJECTION / INTRAVENOUS4680 mgExact identifier — unii candidate
78 equally ranked IID candidates
sodium hydroxideSODIUM HYDROXIDE55X04QC32ISOLUTION / OPHTHALMIC0.05 %w/vExact identifier — unii candidate
174 equally ranked IID candidates
sodium hydroxideSODIUM HYDROXIDE55X04QC32IINJECTION, SOLUTION / INTRATHECALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
hydrochloric acidHYDROCHLORIC ACIDQTT17582CBINJECTION / INTRATHECALADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
hydrochloric acidHYDROCHLORIC ACIDQTT17582CBSOLUTION / EXTRACORPOREALADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
hydrochloric acidHYDROCHLORIC ACIDQTT17582CBINJECTION / SOFT TISSUEADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
sodium thiosulfateSODIUM THIOSULFATEHX1032V43MINJECTION / INTRAVENOUS18 mgExact identifier — unii candidate
10 equally ranked IID candidates
hydrochloric acidHYDROCHLORIC ACIDQTT17582CBGEL / OPHTHALMICADJ PHExact identifier — unii candidate
148 equally ranked IID candidates

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 45.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
N012813-002BLEPHAMIDEPREDNISOLONE ACETATE; SULFACETAMIDE SODIUM0.2%;10%SUSPENSION / OPHTHALMICRLD, Approved before 1982

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 45 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-11-14 07:37:172026-10N012813-002BLEPHAMIDE0.2%;10%SUSPENSION / OPHTHALMICRLD, Approved before 1982d4dbc9d85df4…
2026-10-15 13:18:302026-09N012813-002BLEPHAMIDE0.2%;10%SUSPENSION / OPHTHALMICRLD, Approved before 1982c2088c7a36db…
2026-09-14 22:38:342026-08N012813-002BLEPHAMIDE0.2%;10%SUSPENSION / OPHTHALMICRLD, Approved before 198284e616aacf4f…
2026-08-18 06:07:402026-07N012813-002BLEPHAMIDE0.2%;10%SUSPENSION / OPHTHALMICRLD, Approved before 1982caaa826d4ba7…
2026-02-19 14:30 UTC2026-02N012813-002BLEPHAMIDE0.2%;10%SUSPENSION / OPHTHALMICRLD, Approved before 1982011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N012813-002BLEPHAMIDE0.2%;10%SUSPENSION / OPHTHALMICRLD, Approved before 198231067a03dcf5…
2025-08-23 18:47 UTC2025-08N012813-002BLEPHAMIDE0.2%;10%SUSPENSION / OPHTHALMICRLD, Approved before 19826a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N012813-002BLEPHAMIDE0.2%;10%SUSPENSION / OPHTHALMICRLD, Approved before 1982fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N012813-002BLEPHAMIDE0.2%;10%SUSPENSION / OPHTHALMICRLD, Approved before 1982b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N012813-002BLEPHAMIDE0.2%;10%SUSPENSION / OPHTHALMICRLD, Approved before 198203ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N012813-002BLEPHAMIDE0.2%;10%SUSPENSION / OPHTHALMICRLD, Approved before 19822680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N012813-002BLEPHAMIDE0.2%;10%SUSPENSION / OPHTHALMICRLD, Approved before 19825bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N012813-002BLEPHAMIDE0.2%;10%SUSPENSION / OPHTHALMICRLD, Approved before 1982d8e5a09893c0…
2024-10-29 15:01 UTC2024-10N012813-002BLEPHAMIDE0.2%;10%SUSPENSION / OPHTHALMICRLD, Approved before 1982d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08N012813-002BLEPHAMIDE0.2%;10%SUSPENSION / OPHTHALMICRLD, Approved before 198279d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07N012813-002BLEPHAMIDE0.2%;10%SUSPENSION / OPHTHALMICRLD, Approved before 1982301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06N012813-002BLEPHAMIDE0.2%;10%SUSPENSION / OPHTHALMICRLD, Approved before 19821e350fbaab3a…
2024-05-31 18:47 UTC2024-05N012813-002BLEPHAMIDE0.2%;10%SUSPENSION / OPHTHALMICRLD, Approved before 19828072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N012813-002BLEPHAMIDE0.2%;10%SUSPENSION / OPHTHALMICRLD, RS, Approved before 19825c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04N012813-002BLEPHAMIDE0.2%;10%SUSPENSION / OPHTHALMICRLD, RS, Approved before 19825d02ea3f76ae…
2022-04-04 05:41 UTC2022-04N012813-002BLEPHAMIDE0.2%;10%SUSPENSION / OPHTHALMICRLD, RS, Approved before 19824b0b4de00fa7…
2019-12-13 00:20 UTC2019-12N012813-002BLEPHAMIDE0.2%;10%SUSPENSION / OPHTHALMICRLD, RS, Approved before 198274a2ff9319b5…
2022-03-09 01:35 UTC2022-03N012813-002BLEPHAMIDE0.2%;10%SUSPENSION / OPHTHALMICRLD, RS, Approved before 1982bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12N012813-002BLEPHAMIDE0.2%;10%SUSPENSION / OPHTHALMICRLD, RS, Approved before 1982782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05N012813-002BLEPHAMIDE0.2%;10%SUSPENSION / OPHTHALMICRLD, RS, Approved before 198287673890dc5c…
2021-03-12 10:30 UTC2021-03N012813-002BLEPHAMIDE0.2%;10%SUSPENSION / OPHTHALMICRLD, RS, Approved before 19825aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12N012813-002BLEPHAMIDE0.2%;10%SUSPENSION / OPHTHALMICRLD, RS, Approved before 19828869cabd3fbd…
2020-11-12 02:37 UTC2020-11N012813-002BLEPHAMIDE0.2%;10%SUSPENSION / OPHTHALMICRLD, RS, Approved before 1982c0c555d07b60…
2019-12-14 00:12 UTC2019-12N012813-002BLEPHAMIDE0.2%;10%SUSPENSION / OPHTHALMICRLD, RS, Approved before 19823f01610625f2…
2019-09-15 20:21 UTC2019-09N012813-002BLEPHAMIDE0.2%;10%SUSPENSION / OPHTHALMICRLD, RS, Approved before 1982b00525d2431f…
2019-07-19 19:46 UTC2019-07N012813-002BLEPHAMIDE0.2%;10%SUSPENSION / OPHTHALMICRLD, RS, Approved before 1982ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03N012813-002BLEPHAMIDE0.2%;10%SUSPENSION / OPHTHALMICRLD, Approved before 19826a51e52b5d6a…
2024-02-18 07:12 UTC2024-02N012813-002BLEPHAMIDE0.2%;10%SUSPENSION / OPHTHALMICRLD, Approved before 19821c564ffb4f44…
2023-12-20 04:57 UTC2023-12N012813-002BLEPHAMIDE0.2%;10%SUSPENSION / OPHTHALMICRLD, Approved before 1982ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11N012813-002BLEPHAMIDE0.2%;10%SUSPENSION / OPHTHALMICRLD, Approved before 1982a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10N012813-002BLEPHAMIDE0.2%;10%SUSPENSION / OPHTHALMICRLD, Approved before 19829b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07N012813-002BLEPHAMIDE0.2%;10%SUSPENSION / OPHTHALMICRLD, Approved before 1982a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06N012813-002BLEPHAMIDE0.2%;10%SUSPENSION / OPHTHALMICRLD, Approved before 19823f0d92c62455…
2023-05-13 08:27 UTC2023-05N012813-002BLEPHAMIDE0.2%;10%SUSPENSION / OPHTHALMICRLD, Approved before 1982053a50430f4f…
2023-01-26 05:58 UTC2023-01N012813-002BLEPHAMIDE0.2%;10%SUSPENSION / OPHTHALMICRLD, Approved before 19823bdfa0b2c4d7…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
242d8816-a52b-4df5-ac07-f3ebf13004b869465827-dd70-483e-84c7-ced49af5d1892013-11-15Warnings, Adverse reactionsExact identifier
spl id: 242d8816-a52b-4df5-ac07-f3ebf13004b8
spl set id: 69465827-dd70-483e-84c7-ced49af5d189

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.